Dimitris Tsiodras urges EU Commission to implement joint procurement of critical medicines

Measures to guarantee the availability of captious medicines and code shortages successful “small markets”, Dimitris Tsiodras calls for, successful a question to the European Commission. Specifically, helium asks the Commission whether it is considering the instauration of a associated practice mechanics for associated procurement betwixt Member States facing akin challenges successful presumption of availability, entree to innovative medicines, and addressing shortages.

Underlines that galore innovative pharmaceutical products are not disposable oregon are released with important delays successful immoderate markets, causing inequalities among patients successful the EU, portion smaller Member States thin to wage higher prices

It adds that “the EU faces shortages of 33 medicines and is babelike connected a constricted fig of third-country suppliers for earthy materials and progressive pharmaceutical ingredients (APIs), with the consequences of this dependence becoming evident during the caller COVID-19 pandemic.”
He concludes by referring to the request for concern and the instauration of a much favourable model to fortify the EU’s accumulation capacities, arsenic to trim the EU’s dependence connected 3rd state trading partners with the eventual purpose of enhancing the information and resilience of pharmaceutical proviso chains.

The afloat substance of the question follows:

Question requesting a written reply to the Commission

Subject: Ensuring the availability of captious medicines and addressing shortages successful ‘small markets’

Access to captious medicines varies importantly from 1 Member State to different owed to factors specified arsenic marketplace size.

Many innovative pharmaceutical products are not marketed oregon are launched with important delays successful immoderate markets, causing inequalities betwixt patients successful the EU, portion smaller Member States thin to wage higher prices.

In addition, the EU faces shortages of 33 medicines and depends connected a constricted fig of third-world state suppliers for earthy materials and progressive pharmaceutical ingredients. The consequences of this dependence became evident during the caller COVID-19 pandemic.

Will the Commission say:

1. however it volition promote the associated procurement of captious medicines and different medicines of communal interest, with a peculiar absorption connected “small markets” and whether it volition see establishing a voluntary associated procurement practice mechanics betwixt Member States facing akin challenges successful presumption of availability, entree to innovative medicines and avoiding shortages;

2. How volition it promote concern and make a much favourable model for strengthening the EU’s accumulation capacities?
3. What actions volition it instrumentality to trim dependence connected 3rd state trading partners and heighten the information and resilience of pharmaceutical proviso chains?
How volition it fortify the EU’s capableness to beforehand the competitiveness of its pharmaceutical manufacture and amended its competitiveness?